Despite the short development time of the first COVID19 vaccines, vaccine candidates go through a long journey before they finally reach the people they are supposed to protect. An active role is played by GBA Group Pharma and its 4 subsidiaries: Pharmacelsus, LKF Central Lab, GBA Pharma Labs and ABF. Research and Development is valid for the years 2021, 2022 and 2023 and was first granted to Pharmacelsus in 2015.

Pharmacelsus (member of GBA Group Pharma) is proud to announce that again we have been rewarded with the CIR confirmation for research and innovation. We are very honored that our scientific research has been proofed and recognized with this certificate. This authorization granted by the French Ministry of Higher Education, Research and Development is valid for the years 2021, 2022 and 2023 and was first granted to Pharmacelsus in 2015.

Interview with Dr. Birgit Schumacher, General Manager and Site Manager Martinsried of GBA Pharma GmbH

GBA Pharma GmbH is one of the leading service providers for the pharmaceutical industry in Europe. The company supports its customers along the entire pharmaceutical value chain, from the optimization of drug candidates to global clinical trials. Wirtschaftsforum spoke with Dr. Birgit Schumacher, General Manager and Site Manager Martinsried, about the company's development over the past three years and its importance for patient safety.

GBA Group Pharma has established the analysis of cannabis flowers according to the current German Pharmacopeia (DAB) – monograph. Since March 2017 #cannabis is also available on prescription in Germany under certain conditions. More and more patients are switching to alternative drugs such as medical cannabis if all current alternatives have so far failed to provide relief. Currently, cannabis sold in German pharmacies, is grown almost exclusively abroad.

Dr. Andreas Nechansky has taken over the role of Managing Director of ABF Pharmaceutical Services (Member of GBAGroup). Dr. Nechansky has proven his management skills as Site Manager of ABF since 2019, and brings over 20 years’ experience in the field of Pharmaceutical Development and biologics characterization.

As VP of Research and Analytical Development of JHL Biotech (Taiwan), he became an expert in biosimilar development spanning pre-clinical work to Phase III readiness, including overseeing and directing bioanalytical and immunogenicity operations. As co-founder and COO of Vela Laboratories, he was responsible for Business Development and GMP-certified analytical operations services.